Revotar is a privately held biopharmaceutical company that develops small molecule drugs for a variety of inflammatory disorders.
Revotar was founded in 2000 and is located in Hennigsdorf / Berlin, State of Brandenburg, Germany.
Revotar develops innovative anti-inflammatory drugs, with a strong focus on respiratory indications, especially COPD (chronic obstructive pulmonary disease), known as smoker's lung.
Upside potential for acute lung injury (ALI/ARDS) and Asthma.
Options for other inflammatory diseases.
Revotar is focusing on an emerging, but challenging target space involved in diverse levels of inflammation/immunological response: Glycan binding proteins; involved in host pathogen interactions, initiation of innate immunity, modulation of adaptive immunity and playing an important role in autoimmunity.